Background COVID‐19 can present with lymphopenia and extraordinary complex
multiorgan pathologies that can trigger long‐term sequela. Aims Given that inflammasome …

COVID‐19 is a complex disease, and many difficulties are faced today especially in the
proper choice of pharmacological treatments. The role of antiviral agents for COVID‐19 is …

Lethality of coronavirus disease (COVID-19) during the 2020 pandemic, currently still in the
exponentially accelerating phase in most countries, is critically driven by disruption of the …

A growing body of clinical evidence shows that vascular leakage leads to pulmonary edema
in coronavirus disease 2019 (COVID-19) patients. Coronaviruses including severe acute …

Cathepsin G (CathG) is a serine protease that controls the functional state of immune cells
and is traditionally considered to be one of the effectors of inflammation (1). The substrate …

A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to
seek inhibitors of the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID …

Background In the urgent campaign to develop therapeutics against SARS-CoV-2, natural
products have been an important source of new lead compounds. Results We herein …

Aims Cathepsin C (CTSC) is necessary for the activation of several serine proteases
including neutrophil elastase (NE), cathepsin G and proteinase 3. GSK2793660 is an oral …

A number of inhibitors have been developed for the SARS‐CoV‐2 main protease (MPro) as
potential COVID‐19 medications but little is known about their selectivity. Using enzymatic …

COVID‐19, a global pandemic, has caused over 750,000 deaths worldwide as of August
2020. A vaccine or remedy for SARS‐CoV‐2, the virus responsible for COVID‐19, is …